Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP518 in metastatic castration-resistant prostate cancer
NCT06155084Phase 2Recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of HP518 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hinova Pharmaceuticals Inc.. Started Dec 2023; status: recruiting.
02
Drugs
HP518
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06155084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155084.